Scarica l'app Stockscreener
0.00
100.00%
-15.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.02
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$1.48B
Reddito:
$11.40B
Utile/perdita netta:
$-95.73M
Rapporto P/E:
0.00
EPS:
-2.45
Flusso di cassa netto:
$-64.37M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$15.29
Definium Therapeutics Inc Stock (MNMD) Company Profile
Nome
Definium Therapeutics Inc
Settore
Industria
Telefono
212-220-6633
Indirizzo
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNMD
Definium Therapeutics Inc
|
0.00 | 1.48B | 11.40B | -95.73M | -64.37M | -2.45 |
VRTX
Vertex Pharmaceuticals Inc
|
435.10 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
766.02 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
787.95 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.79 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.81 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Definium Therapeutics Inc Stock (MNMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | Stifel | Buy |
| 2026-04-10 | Iniziato | Piper Sandler | Overweight |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-08-04 | Ripresa | Oppenheimer | Outperform |
| 2025-01-28 | Iniziato | Evercore ISI | Outperform |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-07-24 | Iniziato | ROTH MKM | Buy |
| 2024-05-29 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | Canaccord Genuity | Buy |
| 2022-12-09 | Ripresa | ROTH Capital | Buy |
| 2022-11-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-26 | Iniziato | Oppenheimer | Outperform |
| 2022-08-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Iniziato | ROTH Capital | Buy |
| 2021-06-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Definium Therapeutics Inc Borsa (MNMD) Ultime notizie
Definium Therapeutics (DFTX) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Oppenheimer Adjusts Definium Therapeutics PT to $40 From $25, Maintains Outperform Rating - marketscreener.com
Piper Sandler reiterates Definium stock rating on development plan By Investing.com - Investing.com Canada
The Bull Case For Definium Therapeutics (DFTX) Could Change Following US Psychedelic Policy Momentum - Yahoo Finance
Definium expects three trial readouts for depression, anxiety drug By Investing.com - Investing.com India
DFTX (Definium Therapeutics Inc. Common Shares) posts narrow Q4 2025 EPS miss, trades slightly higher in today’s market session.Earnings Beat - Cổng thông tin điện tử tỉnh Lào Cai
Definium Therapeutics (DFTX) Advances Clinical Programs and Comm - GuruFocus
Definium Highlights DT120 Phase 3 Progress in Depression, Anxiety - TipRanks
Definium Therapeutics accelerates psychedelic treatment momentum with New York investor summit - Traders Union
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics Highlights Clinical Advancements And Commercial Strategy For DT120 ODT - marketscreener.com
Transcript : Definium Therapeutics, Inc.Analyst/Investor Day - marketscreener.com
DFTX: DT120 targets major psychiatric disorders with pivotal data and commercial launch readiness in 2024 - TradingView
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its 311% One Year Surge? - simplywall.st
DFTX: DT-120 aims to transform psychiatric care with rapid, durable relief and broad market potential - TradingView
DFTX Maintained by Leerink Partners -- Price Target Raised to $3 - GuruFocus
DFTX News Today | Why did Definium Therapeutics stock go up today? - MarketBeat
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? - Sahm
Analysts Are Bullish on Top Healthcare Stocks: Definium Therapeutics (DFTX), Iovance Biotherapeutics (IOVA) - The Globe and Mail
Definium Therapeutics (DFTX) stock gains after hours: Here's what's driving the move - MSN
Definium Therapeutics (DFTX) Stock Gains After Hours: Here's What's Driving The Move - Benzinga
Definium Therapeutics Announces New Employee Inducement GrantsApril 20, 2026 - BioSpace
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $38 - Moomoo
Definium Therapeutics Anxiety Drug A Multi-Billion Opportunity: Analyst - MSN
Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump’s Psychedelic Research Order - MEXC Exchange
Definium (DFTX) Stock Rejected Order (+1.90%) 2026-04-20Crowd Breakout Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Definium Therapeutics stock hits 52-week high at 25.63 USD - Investing.com
Definium Therapeutics (DFTX) Stock Hits 52-Week High as Trump Backs Psychedelic Medicine Research - CoinCentral
Definium Therapeutics (DFTX) Stock Soars to New Heights on Trump's Psychedelic Research Order - Blockonomi
Psychedelic Pharmaceutical Companies' Shares Rise Following Executive Order -- Update - Moomoo
Definium Therapeutics stock hits 52-week high at 25.63 USD By Investing.com - Investing.com UK
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - Seeking Alpha
Psychedelic drug makers rally as Trump orders FDA to expedite reviews - Yahoo Finance
Psychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gains - Seeking Alpha
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics (DFTX) Is Up 5.3% After White House Signals Support For Psychedelic Research - simplywall.st
Definium Therapeutics (DFTX) Stock Climbs Following White House Psychedelic Policy Shift - MEXC Exchange
Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments | MEXC News - MEXC Exchange
Definium Therapeutics (DFTX) Stock Rises as White House Moves on Psychedelic Treatments - MEXC
Definium Therapeutics supports White House executive order on mental health innovation, committed to developing psychedelic treatments for mental health - marketscreener.com
Definium Therapeutics Supports White House Executive Order On Mental Health Innovation, Committed To Developing Psychedelic Treatments For Mental Health - TradingView
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments - The Joplin Globe
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026 - TechStock²
Trump signs executive order on psychedelics (ATAI:NASDAQ) - Seeking Alpha
Trump Trade: President to sign order on psychedelic used for PTSD - Yahoo Finance
Is It Too Late To Consider Definium Therapeutics (DFTX) After Its Strong 1 Year Run? - Yahoo Finance
Definium: 'Strong Buy' Maintained On Several Anticipated 2026 Milestones (NASDAQ:DFTX) - Seeking Alpha
DFTX Initiates Coverage On Stifel -- Rating Set to Buy - GuruFocus
Can an LSD candidate do for anxiety what Spravato did for depression? - Pharma Voice
Stifel Initiates Definium Therapeutics at Buy With $30 Price Target - marketscreener.com
Definium Therapeutics Conference Slot Tests Psychedelic Phase III And Funding Story - Sahm
Definium Therapeutics Inc Azioni (MNMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):